10 research outputs found
Statistical modeling of interfractional tissue deformation and its application in radiation therapy planning
In radiation therapy, interfraction organ motion introduces a level of geometric uncertainty into the planning process. Plans, which are typically based upon a single instance of anatomy, must be robust against daily anatomical variations. For this problem, a model of the magnitude, direction, and likelihood of deformation is useful. In this thesis, principal component analysis (PCA) is used to statistically model the 3D organ motion for 19 prostate cancer patients, each with 8-13 fractional computed tomography (CT) images. Deformable image registration and the resultant displacement vector fields (DVFs) are used to quantify the interfraction systematic and random motion. By applying the PCA technique to the random DVFs, principal modes of random tissue deformation were determined for each patient, and a method for sampling synthetic random DVFs was developed.
The PCA model was then extended to describe the principal modes of systematic and random organ motion for the population of patients. A leave-one-out study tested both the systematic and random motion model’s ability to represent PCA training set DVFs. The random and systematic DVF PCA models allowed the reconstruction of these data with absolute mean errors between 0.5-0.9 mm and 1-2 mm, respectively. To the best of the author’s knowledge, this study is the first successful effort to build a fully 3D statistical PCA model of systematic tissue deformation in a population of patients.
By sampling synthetic systematic and random errors, organ occupancy maps were created for bony and prostate-centroid patient setup processes. By thresholding these maps, PCA-based planning target volume (PTV) was created and tested against conventional margin recipes (van Herk for bony alignment and 5 mm fixed [3 mm posterior] margin for centroid alignment) in a virtual clinical trial for low-risk prostate cancer. Deformably accumulated delivered dose served as a surrogate for clinical outcome. For the bony landmark setup subtrial, the PCA PTV significantly (p30, D20, and D5 to bladder and D50 to rectum, while increasing rectal D20 and D5. For the centroid-aligned setup, the PCA PTV significantly reduced all bladder DVH metrics and trended to lower rectal toxicity metrics. All PTVs covered the prostate with the prescription dose
Experimental evidence for sustained carbon sequestration in fire-managed, peat moorlands.
Peat moorlands are important habitats in the boreal region, where they store approximately 30% of the global soil carbon (C). Prescribed burning on peat is a very contentious management strategy, widely linked with loss of carbon. Here, we quantify the effects of prescribed burning for lightly managed boreal moorlands and show that the impacts on peat and C accumulation rates are not as bad as is widely thought. We used stratigraphical techniques within a unique replicated ecological experiment with known burn frequencies to quantify peat and C accumulation rates (0, 1, 3 and 6 managed burns since around 1923). Accumulation rates were typical of moorlands elsewhere, and were reduced significantly only in the 6-burn treatment. However, impacts intensified gradually with burn frequency; each additional burn reduced the accumulation rates by 4.9 g m−2 yr−1 (peat) and 1.9 g C cm−2 yr−1, but did not prevent accumulation. Species diversity and the abundance of peat-forming species also increased with burn frequency. Our data challenge widely held perceptions that a move to 0 burning is essential for peat growth, and show that appropriate prescribed burning can both mitigate wildfire risk in a warmer world and produce relatively fast peat growth and sustained C sequestration
Classification of current anticancer immunotherapies
During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are
now approved by the US Food and Drug Administration and the European Medicines
Agency for use in cancer patients, and many others are being investigated as standalone
therapeutic interventions or combined with conventional treatments in clinical
studies. Immunotherapies may be subdivided into “passive” and “active” based on
their ability to engage the host immune system against cancer. Since the anticancer
activity of most passive immunotherapeutics (including tumor-targeting monoclonal
antibodies) also relies on the host immune system, this classification does not properly
reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer
immunotherapeutics can be classified according to their antigen specificity. While some
immunotherapies specifically target one (or a few) defined tumor-associated antigen(s),
others operate in a relatively non-specific manner and boost natural or therapy-elicited
anticancer immune responses of unknown and often broad specificity. Here, we propose
a critical, integrated classification of anticancer immunotherapies and discuss the clinical
relevance of these approaches
Erratum: Coverage-based treatment planning to accommodate deformable organ variations in prostate cancer treatment [Med Phys 41(10), 101705 (14pp) (2014)]
Erratum: “Coverage-based treatment planning to accommodate deformable organ variations in prostate cancer treatment” [Med. Phys. 41(10), 101705 (14pp.) (2014)]
Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast Cancer
Classification of current anticancer immunotherapies.
During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into passive and active based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches. Oncotarget 2014 Dec 20; 5(24):12472-508